Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090130 | 0.86 | GRM2 (0.62) | GRM2PKMALDH1A1MAPT | |
| SCHEMBL2123223 | 0.86 | GRM2 (0.58) | GRM2RAB9ASMN1; SMN2MAPK1KMT2A | |
| SCHEMBL8122370 | 0.83 | GRM2 (0.47) | GRM2RAB9ASMN1; SMN2MAPK1KMT2A | |
| SCHEMBL8122366 | 0.83 | GRM2 (0.47) | GRM2RAB9ASMN1; SMN2MAPK1KMT2A | |
| SCHEMBL2123310 | 0.83 | GRM2 (0.47) | GRM2RAB9ASMN1; SMN2MAPK1KMT2A | |
| SCHEMBL2123941 | 0.83 | GRM2 (0.47) | GRM2RAB9ASMN1; SMN2MAPK1KMT2A | |
| SCHEMBL2125177 | 0.82 | GRM2 (0.59) | GRM2RAB9AMAPK1KDM4EHTT | |
| SCHEMBL2124258 | 0.79 | GRM2 (0.50) | GRM2MAPK1KMT2AKDM4EPOLB | |
| SCHEMBL3097255 | 0.78 | GRM2 (0.51) | GRM2PKMALDH1A1MAPT | |
| SCHEMBL2023046 | 0.77 | PIK3CG (0.46) | GRM2MAPK1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| EP-2167501-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008150232-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150232-A1 | METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | GRM1, GRM3, GRM2 | GRM2 3/4885RAB9A 2825/4885SMN1; SMN2 2038/4885 |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | GRM1, GRIN1, GRM3 | GRM2 5/4885RAB9A 2973/4885SMN1; SMN2 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.